Arcturus Therapeutics: Overcoming Challenges and Poised for European Expansion
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The ...
manilatimes4d
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
with first data readout expected in summer 2025 European Committee for Medicinal Products for Human Use (CHMP) review of ...
Positive Regulatory Outlook and Imminent PDUFA Date Justify Buy Rating for Applied Therapeutics
In a report released on November 7, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Applied Therapeutics (APLT – ...
Yahoo Finance23d
Novartis Gets CHMP Recommendation for Kisqali in Broader Population
Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...
Investing.com on MSN12d
Biogen down as Morgan Stanley cuts rating on sluggish Alzheimer’s drug launch
Moreover, a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) has impacted prospects. They also cited potential near-term challenges from the launch of Eli Lilly ...
Daily13d
AstraZeneca Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...
FiercePharma16d
Astellas doesn't see eye to eye with Europe on geographic atrophy drug Izervay
Four months after the Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the ...
BioWorld23d
CHMP nods for Korjuny, Alhemo; no, again, for Translarna, masitinib
Catumaxomab, then called Removab, and now reborn with the brand name Korjuny, received a positive opinion for the treatment of malignant ascites from the EMA’s Committee for Medicinal Products for ...
Zacks.com on MSN22d
Novartis Gets CHMP Recommendation for Kisqali in Broader Population
Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...
Pharmabiz22d
EMA’s human medicines committee recommends marketing approval for Accord Healthcare’s Imuldosa, a ustekinumab biosimilar to Stelara
Accord Healthcare Limited (Accord), a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company, announces that the Committee for Medicinal Products for Human Use ...
Hosted on MSN21d
AstraZeneca Receives CHMP's Approval for Wainzua in Europe
AstraZeneca AZN and Ionis Pharmaceuticals IONS announced that the Committee for Medicinal Products for Human Use (CHMP) has ...
Medscape26d
New Flu and Updated COVID Vaccines Greenlighted by Europe
Europe's Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for two vaccines: Fluad (surface antigen, inactivated, adjuvanted) and Flucelvax ...